Paclitaxel Protein-bound Particles For Injectable Suspension (albumin-bound) Injection, Powder, Lyophilized, For Suspension
Product Images NDC 68001-651

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Paclitaxel Protein-bound Particles For Injectable Suspension (albumin-bound) (NDC 68001-651). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Paclitaxel Vial Container Label (Paclitaxel Protein Bound Particles For Inj Susp Vial Rev 0325)

Paclitaxel Vial Container Label (Paclitaxel Protein Bound Particles For Inj Susp Vial Rev 0325)
This is a product label for a medication called Paclitaxel Protein Particles for Injectable Suspension (albumin-bound) in a Single-Dose Vial, intended for intravenous use only. The label also includes information about the functional properties differing from other paclitaxel products and a warning not to substitute it with any other medication. The National Drug Code (NDC) is 68001-651-37. The text also includes details about discarding any unused portion after use.*
FDA Label Image

Paclitaxel Carton Label (Untitled)

Paclitaxel Carton Label (Untitled)
This product is a lyophilized cytotoxic agent containing 100 mg of paclitaxel and approximately 900 mg of human albumin per vial. It needs to be reconstituted with 20 mL of 0.9% Sodium Chloride Injection to achieve a suspension with a concentration of 5 mg/mL of paclitaxel. The formulation is sterile, nonpyrogenic, and preservative-free. It is recommended to store the vial in its original carton at controlled room temperature and the reconstituted suspension in the carton at a specific temperature range to protect it from light. The suspension should be used within 24 hours of reconstitution, and the dosage and infusion rate should be verified. This product is for intravenous use only, and any unused portion should be discarded. It is important to note that the functional properties of this paclitaxel formulation differ from other similar products, so it should not be substituted.*
FDA Label Image

Figure 1 (Paclitaxel Figure 1)

Figure 1 (Paclitaxel Figure 1)
This text is not readable.*
FDA Label Image

Preparation Vial (Paclitaxel Prep Vial)

Preparation Vial (Paclitaxel Prep Vial)
FDA Label Image

Structural Formula For Paclitaxel (Paclitaxel Structure)

Structural Formula For Paclitaxel (Paclitaxel Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.